EUVIMEDEUVIMED entdecken
Crossref

In vitro activity of double and triple antimicrobial combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm

Si-Ho Kim iD, Hye Mee Kim, Doo Ryeon Chung iD, Jae-Hoon Ko, Kyungmin Huh iD, Sun Young Cho, Cheol-In Kang, Kyong Ran Peck

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkag031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Si-Ho Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea. Hauptthemen laut MEDLINE: Biofilms, Pseudomonas aeruginosa, Anti-Bacterial Agents, Carbapenems. Die Arbeit nennt 44 Literaturangaben. Gefördert von: Future Medicine 2030 Project of the Samsung Medical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Pseudomonas aeruginosa is a common microorganism in chronic infections due to biofilm formation and antibiotic resistance. This study aimed to compare the synergistic effects of antibiotic combinations against carbapenem-resistant P. aeruginosa (CRPA) in planktonic and biofilm-embedded states.

Methods

Twelve CRPA bloodstream isolates from the Asian Bacterial Bank (2016–2018) were analysed. The minimum biofilm eradication concentrations (MBECs) were determined using the peg lid system, and antimicrobial interactions were assessed using biofilm checkerboard assays, testing three double combinations (colistin–rifampin, colistin–imipenem, and rifampin–ceftazidime/avibactam) and two triple combinations (colistin–rifampin–imipenem and colistin–rifampin–ceftazidime/avibactam).

Results

The MBEC values of all four antimicrobial agents (rifampin, colistin, imipenem, and ceftazidime/avibactam) were significantly higher than their corresponding minimum inhibitory concentration values (P < 0.001). Although single agents required markedly elevated concentrations to eradicate CRPA biofilms, approximately half of the double and triple antimicrobial combinations demonstrated synergistic activity. In the biofilm phase, synergism rates were comparable between triple combinations (colistin–rifampin–ceftazidime/avibactam, 50%; colistin–rifampin–imipenem, 66%) and double combinations (colistin–rifampin, 42%; rifampin–ceftazidime/avibactam, 42%; colistin–imipenem, 66%). The triple combinations showed lower FBEC indices (colistin–rifampin–imipenem: median 0.17; colistin–rifampin–ceftazidime/avibactam: 0.34) than the corresponding double combinations (colistin–rifampin: 0.53; colistin–imipenem: 0.20; rifampin–ceftazidime/avibactam: 0.78), although these differences were not statistically significant.

Conclusions

Our study provides experimental evidence that antimicrobial combination therapy may offer advantages over single agents for CRPA biofilm eradication, supporting further investigation into the role of such regimens in biofilm-associated infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiofilmsPseudomonas aeruginosaAnti-Bacterial AgentsCarbapenemsMicrobial Sensitivity TestsHumansDrug SynergismColistinRifampinImipenemPseudomonas InfectionsCeftazidimeDrug CombinationsDrug Therapy, CombinationAzabicyclo Compounds

Substanzen

Anti-Bacterial AgentsColistinRifampinCarbapenemsImipenemCeftazidimeDrug CombinationsAzabicyclo Compounds

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea.
  • Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Asia Pacific Foundation for Infectious Diseases (APFID), Foundation, Seoul, South Korea.
  • Center for Infection Prevention and Control, Samsung Medical Center, Seoul, South Korea.

ORCID-Profile: Si-Ho Kim, Doo Ryeon Chung, Kyungmin Huh

Förderung

  • Future Medicine 2030 Project of the Samsung Medical Center

Zitieren

APA

Kim, S. H., Kim, H. M., Chung, D. R., Ko, J. H., Huh, K., Cho, S. Y., Kang, C. I., & Peck, K. R. (2026). In vitro activity of double and triple antimicrobial combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag031

Vancouver

Kim SH, Kim HM, Chung DR, Ko JH, Huh K, Cho SY, et al. In vitro activity of double and triple antimicrobial combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag031

BibTeX
@article{Kim2026,
  author = {Kim, Si-Ho and Kim, Hye Mee and Chung, Doo Ryeon and Ko, Jae-Hoon and Huh, Kyungmin and Cho, Sun Young and Kang, Cheol-In and Peck, Kyong Ran},
  title = {In vitro activity of double and triple antimicrobial combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkag031}
}
Kostenlos starten →